View details of this raise on Seedstage

Shoreview, MN

Developing a minimally invasive therapy for heart failure with preserved ejection fraction.

• Innovative Therapy: Developing a minimally invasive procedure for HFpEF.
• Experienced Leadership: Led by a team with decades of experience in medical device innovation.
• Strong IP Portfolio: Holds exclusive licenses and joint filings with Mayo Clinic.
• Regulatory Progress: Actively enrolling in an FDA-approved Early Feasibility Study.
• Market Potential: Addressing a significant unmet need in cardiology with a growing market.

Heart Failure Solutions is developing a minimally invasive therapy for Heart Failure with Preserved Ejection Fraction (HFpEF), a condition affecting millions with limited treatment options. The company’s PeriCut System aims to relieve cardiac constraints and improve heart function, addressing a significant unmet need in cardiology. Early data from human studies indicate measurable improvements in symptoms, and the company is actively enrolling patients in an FDA-approved Early Feasibility Study.

The leadership team at Heart Failure Solutions brings decades of experience in medical device innovation, supported by experts from the Mayo Clinic. The company has built a strong intellectual property portfolio, including exclusive licenses and joint filings with Mayo Clinic. With a focus on advancing to pivotal trials, Heart Failure Solutions seeks investment to drive commercialization and expand treatment options for HFpEF patients. The company’s efforts are backed by a robust development and regulatory strategy, positioning it to capture a share of the growing market for heart failure treatment devices.

Company Info

Heart Failure Solutions is developing a minimally invasive device to treat Heart Failure with Preserved Ejection Fraction (HFpEF), aiming to improve patient outcomes.

Heart Failure Solutions is focused on developing a minimally invasive therapy for Heart Failure with Preserved Ejection Fraction (HFpEF), a condition affecting millions with limited treatment options. The company is advancing the PeriCut System, an investigational device designed to relieve cardiac constraints and improve heart function. Early data from human studies indicate measurable improvements in symptoms, and the system is currently undergoing an FDA-approved Early Feasibility Study.

The company is supported by a leadership team with extensive experience in medical device innovation and collaboration with renowned institutions like the Mayo Clinic. Heart Failure Solutions aims to address a significant unmet need in cardiology by providing a novel device-based solution for HFpEF, leveraging a strong intellectual property portfolio and a strategic approach to clinical and regulatory pathways.